Advanced search
Publication Cover
Expert Review of Vaccines Volume 22, 2023 - Issue 1
Submit an article Journal homepage
3,217
Views
0
CrossRef citations to date
0
Altmetric
Systematic review and meta-analysis

Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses

Patrick DMC Katotoa Office of the President and CEO, South African Medical Research Council, Cape Town, South Africa;b Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;c Centre for Tropical Diseases and Global Health, Department of Medicine, Catholic University of Bukavu, Bukavu, DR CongoCorrespondence[email protected]
View further author information
,
Mireille AM Kakubud Ministry of Health and Social Services of Namibia, Windhoek, NamibiaView further author information
,
Jacques L. Tamuzib Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South AfricaView further author information
,
Amanda S. Brandb Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South AfricaView further author information
,
Adaeze Ayuke Department of Paediatrics and Child Health, University of Nigeria Teaching Hospital, Enugu, NigeriaView further author information
,
Liliane N. Byamunguf Department of Paediatric, Faculty of Medicine and Health Sciences, University of KwaZulu-Natal, Durban, South AfricaView further author information
,
Charles S. Wiysongeb Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;g Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa;h HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South AfricaORCID Iconhttps://orcid.org/0000-0002-1273-4779View further author information
ORCID Icon &
Glenda Graya Office of the President and CEO, South African Medical Research Council, Cape Town, South AfricaView further author information
 show all
Pages 378-392 | Received 28 Jan 2023, Accepted 14 Apr 2023, Published online: 20 Apr 2023

Figures & data

Figure 1. Study PRISMA flow chart.

Figure 1. Study PRISMA flow chart.

Figure 2a. Forest plot of the proportion of any local reaction among immune-compromised adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 2a. Forest plot of the proportion of any local reaction among immune-compromised adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 2b. (Continued)

Figure 2b. (Continued)

Figure 3a. Forest plot of the proportion of any systemic reaction among immune-compromised adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 3a. Forest plot of the proportion of any systemic reaction among immune-compromised adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 3b. (Continued)

Figure 3b. (Continued)

Figure 4. Forest plot of antibodies neutralization among immune-compromised vs healthy adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 4. Forest plot of antibodies neutralization among immune-compromised vs healthy adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 5. Forest plot of IgG (AU/ml) among immune-compromised vs healthy adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 5. Forest plot of IgG (AU/ml) among immune-compromised vs healthy adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 6a. Forest plot of the proportion of combined any local and any systemic reaction among immune-compromised adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 6a. Forest plot of the proportion of combined any local and any systemic reaction among immune-compromised adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Figure 6b. (Continued)

Figure 6b. (Continued)
Supplemental material

Supplemental Material

Download MS Word (57.9 KB)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.